// App-Quantinova.ai

TPS3134 : An open-label, phase 1b study of NEO-PV-01 with pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous non-small cell lung cancer.

Researchers

Presenter

  • Ramaswamy Govindan

Principal Investigators

  • Mark M. Awad

  • Lisa D Cleary

  • Melissa Ann Moles

  • Richard Gaynor

  • Matthew Jordan Goldstein

  • David R. Spigel

Medical Centers

  • Washington University School of Medicine, St. Louis, MO

  • Massachusetts General Hospital, Boston, MA

  • Neon Therapeutics, Inc., Cambridge, MA

  • Eli Lilly and Company, Indianapolis, IN

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

Locations

  • United States

Companies

  • Neon Therapeutics, I

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Carboplatin

  • Pemetrexed

  • Poly-ICLC

  • NT-002

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • I

Study Id's

  • NCT03380871

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved